2026-04-14T19:31:55Zhttps://uvadoc.uva.es/oai/request

oai:uvadoc.uva.es:10324/599932023-06-29T19:00:31Zcom_10324_1179com_10324_931com_10324_894col_10324_1306

Trejo Velasco, Blanca Estevez Loureiro, Rodrigo Carrasco Chinchilla, Fernando Fernández Vázque, Felipe Arzamendi, Dabit Pan, Manuel Pascual, Isaac Nombela Franco, Luis Amat Santos, Ignacio Jesús Freixa, Xavier Hernández Antolín, Rosa Ana Trillo Nouche, Ramiro Andraka Ikazuriaga, Leire López Mínguez, José R. Sanmiguel Cervera, Dario Sanchis, Juan Diez Gil, José Luis Ruiz Quevedo, Valeriano Urbano Carrillo, Cristóbal Becerra Muñoz, Víctor Manuel Benito González, Tomás Li, Chi Hion Mesa, Dolores Avanzas, Pablo Armijo, Germán Serrador Frutos, Ana María Sanchis, Laura Fernández-Golfín Lobán, Covadonga Cid Álvarez, Belén Hernández García, José María Garrote Coloma, Carmen Fernández Peregrina, Estefanía Romero, Miguel León Arguero, Víctor Cruz González, Ignacio 2023-06-29T08:54:19Z 2023-06-29T08:54:19Z 2021 Journal of Clinical Medicine, 2021, Vol. 10, Nº. 5, 1006 2077-0383 https://uvadoc.uva.es/handle/10324/59993 10.3390/jcm10051006 1006 5 Journal of Clinical Medicine 10 2077-0383 Background: Transcatheter mitral valve repair (TMVR) is an effective therapy for high-risk patients with severe mitral regurgitation (MR) but heart failure (HF) readmissions and death remain substantial on mid-term follow-up. Recently, right ventricular (RV) to pulmonary arterial (PA) coupling has emerged as a relevant prognostic predictor in HF. In this study, we aimed to assess the prognostic value of tricuspid annular plane systolic excursion (TAPSE) to PA systolic pressure (PASP) ratio as a non-invasive measure of RV-to-PA coupling in patients undergoing TMVR with MitraClip (Abbott, CA, USA). Methods: Multicentre registry including 228 consecutive patients that underwent successful TMVR with MitraClip. The sample was divided in two groups according to TAPSE/PASP median value: 0.35. The primary combined endpoint encompassed HF readmissions and all-cause mortality. Results: Mean age was 72.5 ± 11.5 years and 154 (67.5%) patients were male. HF readmissions and all-cause mortality were more frequent in patients with TAPSE/PASP ≤ 0.35: Log-Rank 8.844, p = 0.003. On Cox regression, TAPSE/PASP emerged as a prognostic predictor of the primary combined endpoint, together with STS-Score. TAPSE/PASP was a better prognostic predictor than either TAPSE or PASP separately. Conclusions: TAPSE/PASP ratio appears as a novel prognostic predictor in patients undergoing MitraClip implantation that might improve risk stratification and candidate selection. eng info:eu-repo/semantics/openAccess http://creativecommons.org/licenses/by/4.0/ © 2021 The authors Atribución 4.0 Internacional Cardiac surgery Cardiology Corazón - Cirugía Pulmonary hypertension Hipertensión pulmonar Echocardiography Mitral valve - Diseases - Imaging Heart valves - Diseases - diagnostic imaging Heart - Diseases Corazón - Enfermedades Prognostic role of TAPSE to PASP ratio in patients undergoing MitraClip procedure info:eu-repo/semantics/article